Home > Products > Featured products
Cat. No. Product name CAS No.
DC46690 Gap 27 Featured

Gap 27 is a synthetic connexin-mimetic peptide and acts as a gap junction inhibitor. Gap 27 is highly effective in interrupting co-operative cell-cell interactions, such as the synchronous beating of embryonic cardiomyocytes.

198284-64-9
DC46693 DAMGO Featured

DAMGO (DAGO) is a potent and selective μ opioid receptor agonist with ki of 17 nM.

78123-71-4
DC46694 OT-82 Featured

OT-82 is a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with average IC50s of 13.03   nM in non-HP cancer cells and 2.89   nM in HP cancer cells, respectively.

1800487-55-1
DC57060 Glucocorticoid receptor modulator-1 Featured

A novel Glucocorticoid receptor modulator.

2452396-89-1
DC57061 EHP-101 (VCE- 004.8) Featured

EHP-101 (VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. EHP-101 inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. EHP-101 attenuates adipogenesis and prevents diet-induced obesity. EHP-101 (20 mg/kg/day; i.p.; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice.

1818428-24-8
DC57070 PY-60 Featured

PY-60 is a novel activator of YAP-dependent gene expression.It targets ANXA2 in the Hippo pathway. PY-60 targets ANXA2 to activate YAP[1]. PY-60, a thiazole-substituted derivative, dose-dependently induces luciferase activity in 293A-TEAD-LUC cells in the presence or absence of serum when cells were plated at high cell density (EC50= 1.5 and 1.6 µM, respectively). PY-60 treatment also dose-dependently promoted the association of YAP and TEAD proteins in cells and induced the nuclear localization of YAP in response to increased cell density. PY-60 robustly increases the levels of YAP-controlled transcripts (that is, ANRKD1, CYR61 and CTGF) in 293A cells and other human cell lines (that is, MCF10A, HEK293T, H69 and HaCaT), but did not augment the levels of YAP itself (YAP1)[1]. PY-60 activates a proproliferative, YAP-dependent transcriptional program in the adult animal capable of remodeling the epidermis through proliferation[1]. PY-60 liberates the ANXA2-YAP complex from the cell membrane and competes for ANXA2 binding of phosphoinositides[1]. PY-60 (10 uM; applied topically to the dorsal skin of wild-type adult C57BL/6 mice over the course of 10 days) promotes a dramatic expansion of keratinocytes and K14-positive precursors, as assessed by hematoxylin and eosin and anti-K14 histological staining at the study end. PY-60 results in an approximate doubling of epidermal thickness, a result derived from an increased number of keratinocytes per unit length of skin[1].

2765218-56-0
DC57071 HB007 Featured

HB007 is a novel small-molecule degraders of the small ubiquitin-related modifier 1 (SUMO1).

2387821-46-5
DC60115 Enfuvirtide Acetate Featured

Enfuvirtide acetate salt is a linear synthetic peptide made of 36 amino acids. It has an acetylated N-terminus and a carboxamide C-terminus.

914454-00-5
DC57073 VX-150 Featured

VX-150 (EOS-62073), a NaV1.8 blocker, is currently in a phase II clinical trial for the treatment of patients with acute pain. VX-150 significantly alleviates postoperative pain.

1793080-72-4
DC60116 Pimethixene Featured

Pimethixene or Calmixen is antihistamine and anticholinergic of the thioxanthene chemical class that is often used to treat hyperactivity, anxiety, sleep disorders, and allergy.

314-03-4
DC60117 RS-25344 hydrochloride Featured

RS-25344 HCl is a potent and selective phosphodiesterase (PDE) 4 inhibitor (IC50 values are 0.28, > 100, 160 and 330 nM at PDE4, PDE1, PDE2 and PDE3 respectively). It inhibits eosinophil chemotaxis and increases progressive motility of spermatozoa in vitro.

152815-28-6
DC57076 GPR65 agonist (BTB09089) Featured

GPR65 agonist (BTB09089) is a novel GPR65 agonist.

245728-44-3
DC60118 Fezolinetant HCl Featured

Fezolinetant, also known as ESN-364, is Neurokinin-3 (NK-3) receptor antagonist which has been optimized for use in women’s health, and is being developed for sex-hormone related disorders such as endometriosis, polycystic ovarian syndrome and uterine fibroids.

929016-98-8
DC57080 XEN723 Featured

XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC50s of 45 and 524 nM in mouse and HepG2 cell, respectively.

1072803-08-7
DC57081 FIDAS-3 Featured

FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A). FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-3 has anticancer activities.

1266684-01-8
DC57083 Necrostatin-34 Featured

Necrostatin-34 (Nec-34), a RIPK1 kinase inhibitor, stabilizes RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain.

375835-43-1
DC57085 TAK-653 Featured

TAK 653 (also known as NBI 1065845) is an oral small molecule, positive allosteric modulators of AMPA (AMPA-PAM) receptors

1358751-06-0
DC57090 MIPS-521 Featured

MIPS521 is a positive allosteric modulator of the adenosine A1 receptor.

1146188-19-3
DC60119 YQ128 Featured

YQ128 is a potent and selective second-generation NLRP3 (NOD-like receptor P3) inflammasome inhibitor with an IC50 of 0.30 ± 0.01 μM. Further studies from in vitro and in vivo models confirmed its selective inhibition on the NLRP3 inflammasome and its brain penetration. Furthermore, pharmacokinetic studies in rats at 20 mg/kg indicated extensive systemic clearance and tissue distribution, leading to a half-life of 6.6 h.

2454246-18-3
DC60120 QQN05022(Dot1L-IN-4) Featured

QQN05022, also known as Dot1L-IN-4 is a potent disruptor of telomeric silencing 1-like protein (DOT1L) inhibitor. This molecule was first reported in ACS Medicinal Chemistry Letters (2019), 10(12), 1655-1660. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature.

2565705-02-2
DC60121 NVP-BHG712 isomer Featured

NVP-BHG712 isomer is a regioisomer of NVP-BHG712, which shows conserved non-bonded binding to EPHA2 and EPHB4. BHG-712, is a EphB4 kinase inhibitor and BCR-ABL inhibitor. NVP-BHG712 inhibits EphB4 kinase activity in the low nanomolar range in cellular assays showed high selectivity for targeting the EphB4 kinase when profiled against other kinases in biochemical as well as in cell based assays.

2245892-85-5
DC60122 SC-10914 Featured

SC10914 is a highly potent PARP inhibitor (PARP1 IC50 = 7.87 nM) with potent anti-proliferative activity against human BRCA deficient tumor cells (MDA-MB-436, BRCA1 deficient, IC50 = 4.03 nM, Capan-1 BRCA2 deficient, IC50 = 11.66 nM) and PTEN deficient tumor cells (HGC-27,PTEN deficient, IC50 = 0.35 μM). SC10914 showed potent anti-tumor activity in BRCA1/2 mutant tumor models and better pharmacokinetics profile has the potential to be selected as the clinical candidate for the treatment of treatment of BRCA1/2 deficient cancers.

76985-08-5
Page 293 / Total 443 FirstPrevNextLastGoto